* Adicet Bio Inc ACET.OQ reported a quarterly adjusted
loss
of 35 cents per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -72 cents. The mean expectation of five analysts for the
quarter was for a loss of 39 cents per share. Wall Street
expected results to range from -51 cents to -27 cents per share.
* Reported revenue was zero; analysts expected zero.
* Adicet Bio Inc's reported EPS for the quarter was a loss
of 35
cents.
* The company reported a quarterly loss of $28.02 million.
* Adicet Bio Inc shares had fallen by 38.7% this quarter and
lost 23.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 32.8%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Adicet Bio Inc is
$7.00
This summary was machine generated from LSEG data May 14 at
09:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.39 -0.35 Beat
Dec. 31 2023 -0.69 -0.69 Met
Sep. 30 2023 -0.74 -1.16 Missed
Jun. 30 2023 -0.68 -0.75 Missed